First good manufacturing practice (GMP) batch of the drug substance has been released and 12kg are available to perform all the toxicological and safety studies and to initiate early clinical trials in human subjects, the company said.
Lionel Segard, CEO of Quantum Genomics, said: “The support of Oseo for the development of QGC 001 is exciting reinforcement of the high potential of this first in class drug.”